Skip to content

FDA Grants Priority Review for Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®[1]), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA[2] goal date of 26 April 2025, paving the way for a U.S. commercial launch in 2025[3]. Pixclara (18F-floretyrosine or 18F-FET) is a PET agent for the characterisation of progressive or recurrent glioma from treatment related changes in both adult and pediatric patients. FET PET is already included in international clinical practice guidelines for the imaging of gliomas[4], however there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging commercially available in the U.S. Given its potential to address significant unmet medical need, Pixclara has been… 

more »FDA Grants Priority Review for Brain Cancer Imaging Agent

Canadian households contain dangerous levels of radon gas

(Pugnalom.io) The 2024 Cross-Canada Survey of Radon Exposure in the Residential Buildings of Urban and Rural Communities indicates that radioactive radon exposure in Canada is rising and continues to be a critical public health concern. There are an estimated 10.3 million Canadians living in houses with high radon, increasing their risk of developing lung cancer in… Canadian households contain dangerous levels of radon gas

Pugnalom.io: Daily News About Environmental Topics

  • News

Pugnalom.io erscheint als eine seriöse und qualitativ hochwertige Informationsquelle, die sich auf wissenschaftliche und umweltbezogene Themen spezialisiert hat. Thematische Ausrichtung Die Website konzentriert sich auf wichtige Bereiche wie Umweltschutz, Naturschutz und erneuerbare Energien[1]. Die Berichterstattung umfasst ein breites Spektrum an relevanten Themen: – Wissenschaftliche Forschung und Entwicklung– Umwelttechnologien– Naturschutz und Biodiversität– Nachhaltige Entwicklung– Technologische Innovationen Qualitätsmerkmale Die Artikel basieren auf fundierten wissenschaftlichen Grundlagen und berichten über Forschungsergebnisse renommierter Institutionen wie: – Max-Planck-Institut– Leibniz-Institut– Verschiedene Universitäten und Forschungseinrichtungen[1] Aktualität und Relevanz Die Website wird regelmäßig mit neuen Inhalten aktualisiert und greift zeitgemäße Themen auf, wie beispielsweise: – Gentechnisch veränderte Nutzpflanzen in Ghana[5]– Innovative Technologien im Schienenverkehr[6]– Kreislaufwirtschaft und Nachhaltigkeit[2] Die Berichterstattung ist sachlich und detailliert, wobei komplexe Themen verständlich aufbereitet werden. Die Website eignet sich besonders für Menschen, die sich für wissenschaftliche und umweltbezogene Themen interessieren und dabei auf qualitativ hochwertige… 

more »Pugnalom.io: Daily News About Environmental Topics

Erfolgreiche Phase-III-Studie für Anti-Aging-Behandlung

  • News

Das Schweizer Hautpflegeunternehmen Galderma meldet vielversprechende Ergebnisse aus ihrer Phase-III-Studie für das Produkt RelabotulinumtoxinA (Relfydess), das gegen ausgeprägte Stirnfalten und Krähenfüße entwickelt wurde[1]. Studiendetails In der als READY-4 bezeichneten Studie wurden über 900 Teilnehmer über einen Zeitraum von 12 Monaten behandelt. Die Probanden erhielten bis zu vier Behandlungszyklen im Abstand von mindestens 12 Wochen[1]. Positive Ergebnisse Die Wirksamkeit des Präparats erwies sich als überzeugend. Die meisten Teilnehmer zeigten bereits einen Monat nach der Behandlung eine deutliche Reduzierung der Faltenbildung[1]. Besonders bemerkenswert war die hohe Zufriedenheitsrate – mindestens 84% der Teilnehmer äußerten sich einen Monat nach der Behandlung positiv über die Ergebnisse[1]. Sicherheitsprofil Die Studie bestätigte auch die Sicherheit des Produkts. Nur bei 18% der Teilnehmer traten behandlungsbedingte Nebenwirkungen auf, die durchweg als mild bis moderat eingestuft wurden[1]. Markteinführung RelabotulinumtoxinA, das mit der innovativen PEARL-Technologie hergestellt wird, hat bereits das europäische… 

more »Erfolgreiche Phase-III-Studie für Anti-Aging-Behandlung

CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction

Caliway Biopharmaceuticals (Caliway) completed CBL-514 Phase 2b study for non-surgical fat reduction (CBL-0205, clinicaltrials.gov ID: NCT06005441) on October 22nd, 2024, with the topline results anticipated in Q1 2025. CBL-0205, the last of the two CBL-514 Phase 2b studies for fat reduction, was designed in accordance with the U.S. FDA recommendations for the upcoming Pivotal Phase 3 study. The possible success of two Phase 2b studies meeting endpoints will make CBL-514 the first fat reduction product for large area to enter the Phase 3 study. CBL-514 is a combination of multiple APIs, including CBL-A1 and CBL-A2. The CBL-0205 study is a multicenter, single-blinded, randomized, placebo-controlled Phase 2b trial designed to evaluate the efficacy, safety, and tolerability of CBL-514 versus its individual API, CBL-A1 and CBL-A2, as well as the placebo. A total of 173 participants were enrolled and randomly allocated to… 

more »CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction

Rise Therapeutics secures funding

Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH) to enable infrastructure improvement that will scale GMP production and accelerate quality assurance (QA) and quality control (QC), significantly enhancing its biologics drug manufacturing capabilities. This Commercial Readiness Pilot (CRP) Program SBIR award will also support Phase 2 clinical GMP manufacturing to advance Rise Therapeutics‘ R-3750 program currently completing a Phase 1 proof-of-concept clinical trial in patients suffering from ulcerative colitis.

Chinese Anti-Tumor Tablets: Investigational New Drug (IND) Application Accepted

On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company’s Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of tumors. The application has been accepted by the Center for Drug Evaluation of National Medical Products Administration of China (Application Number: CXHL2401105, CXHL2401107, CXHL2401108). Malignant tumors are one of the main causes leading to human death. Although clinical treatments have been significantly improved, most tumors are still incurable. The drug resistance, tumor recurrence and metastasis still are the biggest threat to long-term survival of patients. Particularly, Malignant brain tumors and brain metastasis  not only brings direct life hazards but also has a natural barrier for drug efficacy due to the blood-brain barrier. Therefore, developing new anti-tumor drugs with good brain permeability has become a hot and… 

more »Chinese Anti-Tumor Tablets: Investigational New Drug (IND) Application Accepted

Dehydration leads to muscle cramps in IRONMAN triathletes

PULLMAN, Washington – As athletes prepare to dive into Hawaiian waters for the first leg of the IRONMAN World Championship on Oct. 26, they might want to pay a little more attention to the water in their bodies. Contrary to previous findings, a study led by Washington State University that examined three decades of IRONMAN elite competition found a link between dehydration and exercise-induced muscle cramps. The study, published in the Clinical Journal of Sport Medicine, drew on medical data from more than 10,500 triathletes and found a strong association between dehydration and participants seeking treatment for muscle cramps during competition. While many common theories suggest that electrolyte imbalances or potassium and salt levels contribute to cramps, this study found no evidence of that, aligning with other recent research. Muscle cramps are among the most common complaints in triathlons. According to a… 

more »Dehydration leads to muscle cramps in IRONMAN triathletes

Wearable cameras allow AI to detect medication errors

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence, detects potential errors in medication delivery. In a test whose results were published today, the video system recognized and identified, with high proficiency, which medications were being drawn in busy clinical settings. The AI achieved 99.6% sensitivity and 98.8% specificity at detecting vial-swap errors. The findings are reported Oct. 22 in npj Digital Medicine. The system could become a critical safeguard, especially in operating rooms, intensive-care units and emergency-medicine settings, said co-lead author Dr. Kelly Michaelsen, an assistant professor of anesthesiology and pain medicine at the University of Washington School of Medicine. “The thought of being able to help patients in real time or to prevent a medication error before it happens is very powerful,” she said. “One can hope… 

more »Wearable cameras allow AI to detect medication errors

Rapid genome analysis of a greyhound sets new standard for species conservation research

(Pugnalom.io) Der fortschreitende weltweite Verlust an Artenvielfalt macht es zunehmend erforderlich, genetische Informationen bedrohter Arten schnell zu erfassen und auszuwerten. Die Abteilung für Humangenetik des Bioscientia Instituts für Medizinische Diagnostik GmbH in Ingelheim am Rhein und das hessische LOEWE-Zentrum für Translationale Biodiversitätsgenomik (LOEWE-TBG) haben in einem Kooperationsprojekt in weniger als einer Woche das komplette Genom eines… Schnelle Genomanalyse eines Windhundes setzt neuen Maßstab für Artenschutz-Forschung